140 related articles for article (PubMed ID: 38073116)
21. What to use to treat AML: the role of emerging therapies.
Thol F
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):16-23. PubMed ID: 34889359
[TBL] [Abstract][Full Text] [Related]
22. Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia.
Chen N; Pan J; Zhou Y; Mao L; Lou Y; Qian J; Xu G; Wei J; Zhou D; Shou L; Huang L; Yan M; Zeng H; Fan C; Wu G; Feng W; Tong H; Jin J; Wang H
Br J Haematol; 2024 Mar; 204(3):861-870. PubMed ID: 37939390
[TBL] [Abstract][Full Text] [Related]
23. Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia.
Hosono N; Yokoyama H; Aotsuka N; Ando K; Iida H; Ishikawa T; Usuki K; Onozawa M; Kizaki M; Kubo K; Kuroda J; Kobayashi Y; Shimizu T; Chiba S; Nara M; Hata T; Hidaka M; Fujiwara SI; Maeda Y; Morita Y; Kusano M; Lu Q; Miyawaki S; Berrak E; Hasabou N; Naoe T
Int J Clin Oncol; 2021 Nov; 26(11):2131-2141. PubMed ID: 34363558
[TBL] [Abstract][Full Text] [Related]
24. Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis.
Shimony S; Canaani J; Kugler E; Nachmias B; Ram R; Henig I; Frisch A; Ganzel C; Vainstein V; Moshe Y; Aumann S; Yeshurun M; Ofran Y; Raanani P; Wolach O
Ann Hematol; 2022 Sep; 101(9):2001-2010. PubMed ID: 35739428
[TBL] [Abstract][Full Text] [Related]
25. [Successful treatment with gilteritinib for relapsed acute myeloid leukemia with FLT3-N676K mutation].
Miyajima T; Harada S; Ogasawara R; Yokoyama E; Izumiyama K; Mori A; Saito M; Morioka M; Chi S; Minami Y; Kondo T
Rinsho Ketsueki; 2022; 63(1):51-54. PubMed ID: 35135952
[TBL] [Abstract][Full Text] [Related]
26. Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.
Perl AE; Hosono N; Montesinos P; Podoltsev N; Martinelli G; Panoskaltsis N; Recher C; Smith CC; Levis MJ; Strickland S; Röllig C; Groß-Langenhoff M; Chou WC; Lee JH; Yokoyama H; Hasabou N; Lu Q; Tiu RV; Altman JK
Blood Cancer J; 2022 May; 12(5):84. PubMed ID: 35637252
[TBL] [Abstract][Full Text] [Related]
27. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
Antar AI; Otrock ZK; Jabbour E; Mohty M; Bazarbachi A
Leukemia; 2020 Mar; 34(3):682-696. PubMed ID: 31919472
[TBL] [Abstract][Full Text] [Related]
28. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.
Perl AE; Larson RA; Podoltsev NA; Strickland S; Wang ES; Atallah E; Schiller GJ; Martinelli G; Neubauer A; Sierra J; Montesinos P; Recher C; Yoon SS; Maeda Y; Hosono N; Onozawa M; Kato T; Kim HJ; Hasabou N; Nuthethi R; Tiu R; Levis MJ
Transplant Cell Ther; 2023 Apr; 29(4):265.e1-265.e10. PubMed ID: 36526260
[TBL] [Abstract][Full Text] [Related]
29. Prevalence and prognostic significance of FLT3 gene mutations in patients with acute leukaemia: analysis of patients from the Shanghai Leukaemia Co-operative Group.
Wang W; Wang XQ; Xu XP; Lin GW
J Int Med Res; 2010; 38(2):432-42. PubMed ID: 20515557
[TBL] [Abstract][Full Text] [Related]
30. Enasidenib in mutant
Stein EM; DiNardo CD; Pollyea DA; Fathi AT; Roboz GJ; Altman JK; Stone RM; DeAngelo DJ; Levine RL; Flinn IW; Kantarjian HM; Collins R; Patel MR; Frankel AE; Stein A; Sekeres MA; Swords RT; Medeiros BC; Willekens C; Vyas P; Tosolini A; Xu Q; Knight RD; Yen KE; Agresta S; de Botton S; Tallman MS
Blood; 2017 Aug; 130(6):722-731. PubMed ID: 28588020
[TBL] [Abstract][Full Text] [Related]
31. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
Intlekofer AM; Shih AH; Wang B; Nazir A; Rustenburg AS; Albanese SK; Patel M; Famulare C; Correa FM; Takemoto N; Durani V; Liu H; Taylor J; Farnoud N; Papaemmanuil E; Cross JR; Tallman MS; Arcila ME; Roshal M; Petsko GA; Wu B; Choe S; Konteatis ZD; Biller SA; Chodera JD; Thompson CB; Levine RL; Stein EM
Nature; 2018 Jul; 559(7712):125-129. PubMed ID: 29950729
[TBL] [Abstract][Full Text] [Related]
32. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
[TBL] [Abstract][Full Text] [Related]
33. Myelomonocytic differentiation of leukemic blasts accompanied by differentiation syndrome in a case of
Kondo T; Onozawa M; Fujisawa S; Harada S; Ogasawara R; Izumiyama K; Saito M; Morioka M; Mori A; Teshima T
Hematology; 2021 Dec; 26(1):256-260. PubMed ID: 33631087
[No Abstract] [Full Text] [Related]
34. Gilteritinib: potent targeting of FLT3 mutations in AML.
Levis M; Perl AE
Blood Adv; 2020 Mar; 4(6):1178-1191. PubMed ID: 32208491
[TBL] [Abstract][Full Text] [Related]
35. A Relapsing Meningeal Acute Myeloid Leukaemia FLT3-ITD+ Responding to Gilteritinib.
Perrone S; Ortu La Barbera E; Viola F; Cipollone E; Scerpa MC; Siniscalchi R; Ottone T; Voso MT; Cimino G
Chemotherapy; 2021; 66(4):134-138. PubMed ID: 34515081
[TBL] [Abstract][Full Text] [Related]
36. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
Mori M; Kaneko N; Ueno Y; Yamada M; Tanaka R; Saito R; Shimada I; Mori K; Kuromitsu S
Invest New Drugs; 2017 Oct; 35(5):556-565. PubMed ID: 28516360
[TBL] [Abstract][Full Text] [Related]
37. Treatment of Relapsed Acute Myeloid Leukemia.
Thol F; Ganser A
Curr Treat Options Oncol; 2020 Jun; 21(8):66. PubMed ID: 32601974
[TBL] [Abstract][Full Text] [Related]
38. [Gilteritinib for pediatric FLT3 internal tandem duplication-positive recurrent acute myeloid leukemia].
Fukuoka K; Tsumura Y; Noguchi J; Sugawa M; Takaki T; Hiraki T; Inoue K; Mitani Y; Tomita O; Oshima K; Yanagi M; Isobe K; Mori M; Arakawa Y; Koh K
Rinsho Ketsueki; 2020; 61(4):322-326. PubMed ID: 32378574
[TBL] [Abstract][Full Text] [Related]
39. Successful bridge therapy of gilteritinib to cord blood transplantation in relapsed acute myeloid leukemia after bone marrow transplantation.
Kamitani I; Saito T; Yokoyama H; Nakano A; Ishii H; Tanoue S; Hattori D; Oshima S; Ishii S; Gunji T; Fukushima R; Katsube A; Shimada T; Nishiwaki K; Dobashi N; Yano S
J Infect Chemother; 2021 Apr; 27(4):639-641. PubMed ID: 33214069
[TBL] [Abstract][Full Text] [Related]
40. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.
McMahon CM; Ferng T; Canaani J; Wang ES; Morrissette JJD; Eastburn DJ; Pellegrino M; Durruthy-Durruthy R; Watt CD; Asthana S; Lasater EA; DeFilippis R; Peretz CAC; McGary LHF; Deihimi S; Logan AC; Luger SM; Shah NP; Carroll M; Smith CC; Perl AE
Cancer Discov; 2019 Aug; 9(8):1050-1063. PubMed ID: 31088841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
